Dry Eye

According to the company, an additional trial is required to show positive effects on the treatment of ocular symptoms in dry eye disease.

2 cases illustrate the importance of ocular surface optimization.

Using the NEI protocol for addressing corneal staining, researchers used 5 microliters of 2%, non preserved fluorescein and then evaluated corneal staining.

By taking a proactive approach to treatment, identify the “silent sufferers.”

According to Sun Pharmaceutical Industries, the study design mirrors real-world experience with dry eye disease, including allowing use of artificial tears and measurement of CFS in all 5 corneal zones.

The FDA recalled 26 eye drops due to risk of infection and possible vision loss.

These toxic offenders can be found in various pathways and can pollute the ocular surface.

Educating patients about the importance of consistent care is key.

TearCare provides significant improvements in dry eye signs and symptoms, superior to Restasis in tear film break-up time improvements.

Dr David Kading explores various treatment options for MGD, including thermal pulsation and light-based therapies such as low-level and intense pulsed light (IPL).

Dr David Kading elaborates on the diagnostic criteria for MGD and provides insights into his interpretation of meibography and meibomian gland expression results.

Dr David Kading shares a patient case of MGD demonstrating gradual improvement through thermal pulsation therapy.

Dr David Kading presents a case of MGD associated with extreme inflammatory reaction.

Retain patients and recapture dropouts with a tandem approach.

Collaboration between ophthalmologists, optometrists can boost early detection.

A rapid fire session details what's in the pipeline for ocular surface dryness therapies.

Aldeyra Therapeutics encounters a significant setback, with its stock value plummeting nearly 70%. The FDA indicates a potential Complete Response Letter (CRL) for reproxalap, a dry eye treatment, despite a scheduled Prescription Drug User Fee Act (PDUFA) date of November 23, 2023.

Tracy Doll, OD, FAAO, chats about the AAOpt session "Sunny With a Chance of Tears: What's in the Forecast for Ocular Surface Dryness Therapies?"

Lisa Hornick, OD, MBA, FAAO, chats about her AAOpt presentations, "Dry Eye Jeopardy" and "Sunny with a Chance of Tears of Tears: What's in the Forecast for Ocular Surface Dryness Therapies."

Hear what is new in the world of ocular surface disease, and what's coming down the pipeline.

At AAOpt, Justin Schweitzer, OD, FAAO, and Selina McGee, OD, FAAO, Dipl ABO, discuss the intersection of dry eye and glaucoma.

Bausch + Lomb is gearing up for the American Academy of Optometry (AAOpt) annual meeting, which is poised to convene in New Orleans from Oct. 11-14, 2023.

Easy-to-use modality offers exciting benefits for patients.